Table 2 Undiscounted lifetime risk-reduction in burden of disease for bases case analyses, by duration of vaccine protection
From: A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
| Â | No herd immunity | With herd immunity | ||
|---|---|---|---|---|
| Â | HPV 16/18 | HPV 16/18 + cross-protection | HPV 16/18 | HPV 16/18 + cross-protection |
Cancer Cases | Â | Â | Â | Â |
No. cases no vaccination | 822 | 822 | 822 | 822 |
No. cases with vaccination | 432 | 365 | 369 | 189 |
No. cases prevented | 390 | 457 | 453 | 633 |
% reduction | 47.4% | 55.6% | 55.1% | 77.0% |
vaccine duration = 30 y | 22.3% | 26.2% | 34.0% | 61.6% |
vaccine duration = 10 y | 9.0% | 9.0% | 21.1% | 51.8% |
Cancer Deaths | Â | Â | Â | Â |
No. deaths no vaccination | 351 | 351 | 351 | 351 |
No. deaths with vaccination | 183 | 155 | 150 | 76 |
No. deaths prevented | 168 | 196 | 201 | 275 |
% reduction | 47.9% | 55.8% | 57.3% | 78.3% |
vaccine duration = 30 y | 12.8% | 15.1% | 29.1% | 57.7% |
vaccine duration = 10 y | 4.0% | 4.0% | 20.8% | 51.4% |